MCID: BCT002
MIFTS: 56

Bacterial Vaginosis

Categories: Reproductive diseases

Aliases & Classifications for Bacterial Vaginosis

MalaCards integrated aliases for Bacterial Vaginosis:

Name: Bacterial Vaginosis 12 72 51 3 14 69 59
Vaginosis, Bacterial 41

Classifications:



External Ids:

Disease Ontology 12 DOID:3385
MeSH 41 D016585
NCIt 46 C116973
UMLS 69 C0085166

Summaries for Bacterial Vaginosis

PubMed Health : 59
About bacterial vaginosis: In bacterial vaginosis (sometime abbreviated as BV) much larger numbers of bacteria grow inside of the vagina than would normally just be there. This increase in bacteria is usually not dangerous and it often goes unnoticed, but it can cause a strong-smelling vaginal discharge and be very unpleasant. It also increases the risk of a vaginal infection. Antibiotics can provide effective treatment.

MalaCards based summary : Bacterial Vaginosis, also known as vaginosis, bacterial, is related to vaginitis and vulvovaginitis. An important gene associated with Bacterial Vaginosis is PEPD (Peptidase D), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Acetylcysteine and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and breast, and related phenotypes are cardiovascular system and hematopoietic system

CDC : 3 Some women with BV don't know they have it because they have no symptoms. Having BV can increase your chance of getting an STD.

Disease Ontology : 12 A vaginitis that is characterized by a grayish vaginal discharge usually of foul odor and the presence of Gardnerella vaginalis.

Wikipedia : 72 Bacterial vaginosis (BV) is a disease of the vagina caused by excessive growth of bacteria. Common... more...

Related Diseases for Bacterial Vaginosis

Diseases related to Bacterial Vaginosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 306)
# Related Disease Score Top Affiliating Genes
1 vaginitis 32.2 CXCL8 IL1B IL6 PRF1
2 vulvovaginitis 30.8 CXCL8 IL10
3 endometritis 30.6 IL1B IL6 TNF
4 cystitis 29.5 CXCL8 IL6 TLR4 TNF
5 reactive arthritis 29.5 IL10 IL6 TNF
6 chorioamnionitis 28.7 CXCL8 IL1A IL1B IL6 TLR4 TNF
7 chlamydia 28.6 CXCL8 IL10 IL1B IL6 TLR2 TLR4
8 arthritis 28.4 CXCL8 IL10 IL1A IL1B IL6 TNF
9 periodontitis 27.9 CXCL8 IL10 IL1A IL1B IL6 TLR2
10 periodontal disease 27.7 CXCL8 DEFB4A IL1A IL1B IL6 TLR2
11 vaginal discharge 11.4
12 cervicitis 10.6
13 candidiasis 10.5
14 polyposis, gastric 10.5 IL1B TNF
15 trichomoniasis 10.4
16 staphylococcal toxic shock syndrome 10.4 IL1B TNF
17 kashin-beck disease 10.4 IL1B TNF
18 peptic esophagitis 10.4 CXCL8 IL1B
19 vulvar vestibulitis syndrome 10.4 IL1B TNF
20 chronic follicular conjunctivitis 10.4 IL1A IL1B
21 spondylarthropathy 10.4 TLR4 TNF
22 burns 10.4 IL1B TNF
23 tympanosclerosis 10.4 TLR4 TNF
24 vulvovaginal candidiasis 10.3
25 leukoregulin 10.3 CXCL8 IL1A
26 campylobacteriosis 10.3 IL1B TLR4
27 mycobacterium chelonae 10.3 CXCL8 TLR2
28 cerebral artery occlusion 10.3 IL1B TNF
29 opisthorchiasis 10.3 CXCL8 IL1B
30 mycobacterium kansasii 10.3 CXCL8 TLR2
31 scorpion envenomation 10.3 IL6 TNF
32 aging 10.3
33 skin conditions 10.3 IL1A TNF
34 crohn's colitis 10.3 CXCL8 IL1B TNF
35 dental pulp disease 10.3 CXCL8 IL1B TNF
36 angioimmunoblastic lymphadenopathy with dysproteinemia 10.3 IL6 TNF
37 critical limb ischemia 10.3 IL6 TNF
38 uremic pruritus 10.2 IL1B IL6
39 atrophic gastritis 10.2 CXCL8 IL1B TNF
40 duodenal ulcer 10.2 CXCL8 IL1B TNF
41 denture stomatitis 10.2 CXCL8 IL6
42 euthyroid sick syndrome 10.2 IL1B IL6
43 surfactant metabolism dysfunction, pulmonary, 1 10.2
44 surfactant metabolism dysfunction, pulmonary, 4 10.2
45 surfactant metabolism dysfunction, pulmonary, 3 10.2
46 punctate inner choroidopathy 10.2 IL10 TNF
47 retinitis pigmentosa 60 10.2 IL1B TNF
48 null-cell leukemia 10.2 IL6 TNF
49 papillary conjunctivitis 10.2 CXCL8 IL6
50 systemic onset juvenile idiopathic arthritis 10.2 IL1B PRF1 TNF

Graphical network of the top 20 diseases related to Bacterial Vaginosis:



Diseases related to Bacterial Vaginosis

Symptoms & Phenotypes for Bacterial Vaginosis

MGI Mouse Phenotypes related to Bacterial Vaginosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.11 TLR4 TNF IL6 IL10 PEPD IL1A
2 hematopoietic system MP:0005397 10.09 TLR4 TNF IL6 IL10 PEPD IL1A
3 immune system MP:0005387 10.07 TLR4 TNF IL6 IL10 LAP3 PEPD
4 homeostasis/metabolism MP:0005376 10.06 TLR4 TNF TLR2 IL6 IL10 PEPD
5 integument MP:0010771 9.97 TLR4 TNF IL10 PEPD IL1A PRF1
6 liver/biliary system MP:0005370 9.73 TLR4 TNF IL6 IL10 PRF1 TLR2
7 muscle MP:0005369 9.63 TLR4 TNF TLR2 IL6 IL10 PEPD
8 neoplasm MP:0002006 9.56 TLR4 TNF IL10 IL1A PRF1 IL1B
9 nervous system MP:0003631 9.23 TLR4 TNF TLR2 IL6 IL10 PEPD

Drugs & Therapeutics for Bacterial Vaginosis

PubMedHealth treatment related to Bacterial Vaginosis: 59

Symptomatic bacterial vaginosis is usually treated using antibiotics to kill the germs. Treatments are available in tablet form or as a suppository or cream for direct application.Another treatment option is suppositories or capsules containing living lactic acid bacteria. These treatments are designed to protect the vaginal flora and restore the correct balance. There is not yet enough evidence on the benefits of this method.Some women also try things like putting tampons that have been soaked in tea tree oil or natural yogurt in their vagina to create a more acidic environment for the vaginal flora, but there has not yet been any research about how effective or safe these kinds of home remedies are.

Drugs for Bacterial Vaginosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
2
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 443-48-1 4173
3
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 18323-44-9 29029
4
Desogestrel Approved Phase 4,Phase 2,Phase 3 54024-22-5 40973
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-28-2 5757
6
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3 57-63-6 5991
7
Etonogestrel Approved, Investigational Phase 4,Phase 2,Phase 3 54048-10-1 6917715 40976
8
Tinidazole Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19387-91-8 5479
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 22916-47-8 4189
10
Nystatin Approved, Vet_approved Phase 4,Phase 3 1400-61-9 11953884
11
Azithromycin Approved Phase 4,Phase 2,Phase 3 83905-01-5 53477736 447043 55185
12
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
13
Neomycin Approved, Vet_approved Phase 4,Phase 3 1404-04-2 8378
14
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
15
Clotrimazole Approved, Vet_approved Phase 4,Phase 3 23593-75-1 2812
16
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
17
Ephedrine Approved Phase 4,Phase 2,Phase 3 299-42-3 9294
18
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3 90-82-4 7028
19
Norethindrone Approved Phase 4 68-22-4 6230
20 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Early Phase 1
21 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
22 Antidotes Phase 4
23 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
24 Antioxidants Phase 4
25 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
26 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Antiviral Agents Phase 4
28 Expectorants Phase 4
29 N-monoacetylcystine Phase 4
30 Protective Agents Phase 4,Phase 2
31 Respiratory System Agents Phase 4,Phase 2,Phase 3
32 Clindamycin palmitate Phase 4,Phase 3,Phase 2,Early Phase 1
33 Clindamycin phosphate Phase 4,Phase 3,Phase 2,Early Phase 1
34 Contraceptive Agents Phase 4,Phase 2,Phase 3
35 Contraceptives, Oral Phase 4,Phase 2,Phase 3
36 Estradiol 17 beta-cypionate Phase 4,Phase 2,Phase 3
37 Estradiol 3-benzoate Phase 4,Phase 2,Phase 3
38 Estradiol valerate Phase 4,Phase 2,Phase 3 979-32-8
39 Estrogens Phase 4,Phase 2,Phase 3
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
41 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
42 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
43 Polyestradiol phosphate Phase 4,Phase 2,Phase 3
44 Progestins Phase 4,Phase 2,Phase 3
45 Alkylating Agents Phase 4,Phase 3,Phase 2,Early Phase 1
46 Antifungal Agents Phase 4,Phase 3,Phase 2,Early Phase 1
47 Ionophores Phase 4,Phase 3
48 Antitubercular Agents Phase 4
49 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
50 Autonomic Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 166)

# Name Status NCT ID Phase Drugs
1 Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
2 Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
3 Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
4 Treatment of Bacterial Vaginosis (BV) With Tinidazole Completed NCT00334633 Phase 4 tinidazole, metronidazole
5 Treatment of Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
6 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study Completed NCT00464542 Phase 4 Metronidazole
7 Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
8 Treatment of Bacterial Vaginosis Combined With Human Lactobacilli Completed NCT01245322 Phase 4 lactobacilli
9 Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis Completed NCT00642980 Phase 4 Clindamycin;Placebo;Clindamycin
10 Safety and Tolerability of Metronidazole Gel 1.3% Completed NCT02392026 Phase 4 Metronidazole Gel
11 N-Acetyl Cysteine for Prevention of Preterm Birth Completed NCT00568113 Phase 4 acetylcysteine in arm 1
12 Examining the Impact of Tampon Use on the Vaginal Microbiota Completed NCT03346759 Phase 4
13 Clindamycin to Reduce Preterm Birth in a Low Resource Setting Completed NCT01800825 Phase 4 Clindamycin;Placebo
14 Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis Completed NCT02444481 Phase 4 Polygynax combinaison of polymyxin, Neomycin and Nystatin
15 DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women Completed NCT01874158 Phase 4
16 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
17 Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections Completed NCT01697826 Phase 4 ClinSupV3 -soft gelatin capsule;ClinSupV3ER- Extended release tablet
18 PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra Completed NCT00269620 Phase 4 ethinyl estradiol/etonogestrel vaginal ring;ethinyl estradiol/norelgestromin transdermal contraceptive
19 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis Recruiting NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
20 Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis Recruiting NCT02042287 Phase 4 Metronidazole
21 Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
22 Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis Recruiting NCT03446443 Phase 4 Honghe Fujie lotion;Metronidazole Suppositories
23 The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Recruiting NCT02905890 Phase 4 Norethisterone enantate
24 Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity Recruiting NCT02445989 Phase 4 NuvaRing
25 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Recruiting NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
26 Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity Recruiting NCT02432404 Phase 4 NuvaRing
27 Colposeptine for the Treatment of Bacterial Vaginosis Terminated NCT01153958 Phase 4 Colposeptine;Metronidazole
28 Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis Unknown status NCT02173184 Phase 3
29 A Pilot Open-label Randomized Study of Lactofiltrum in Women With Bacterial Vaginosis Unknown status NCT01089348 Phase 2, Phase 3 Lactofiltrum + Metronidazole;Metronidazole
30 The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
31 Va-Sense - Bacterial Vaginosis Once A Week Screening And Treatment To Reduce Infective Complications, Abortion And Preterm Delivery In Pregnant Women With Previous Preterm Delivery Unknown status NCT01152528 Phase 3
32 Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
33 Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Unknown status NCT00491270 Phase 3
34 Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections Unknown status NCT02186145 Phase 3 Association of metronidazole; nystatin and dexamethasone;Flagyl
35 Maternal Genitourinary Infections and Adverse Perinatal Outcomes Unknown status NCT01572532 Phase 3
36 Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
37 Bacterial Vaginosis Home Screening to Prevent STDs Completed NCT00667368 Phase 3 Metronidazole
38 Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis Completed NCT01471457 Phase 2, Phase 3 Trimo-San gel
39 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577537 Phase 3 1% SPL7013 Gel;Placebo
40 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577238 Phase 3 1% SPL7013 Gel;Placebo
41 Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis Completed NCT01125410 Phase 3 Dequalinium chloride;Clindamycin
42 A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02418845 Phase 3 SYM-1219;Placebo
43 Safety and Efficacy Study to Treat Bacterial Vaginosis Completed NCT01621399 Phase 3 Product 55394;Placebo Vehicle (non-treatment)
44 Lcr35® for Bacterial Vaginosis Prevention Completed NCT01160796 Phase 3 placebo;Lcr35®
45 Treatment of Bacterial Vaginosis With Oral Tinidazole Completed NCT00229216 Phase 3 Tinidazole
46 Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) Completed NCT02237950 Phase 3 Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
47 Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole Completed NCT02452866 Phase 3 SYM-1219
48 Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) Completed NCT02236156 Phase 3 Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
49 The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis Completed NCT01258556 Phase 2, Phase 3
50 BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study Completed NCT00799214 Phase 2, Phase 3 Placebo;Boric acid;Metronidazole

Search NIH Clinical Center for Bacterial Vaginosis

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: vaginosis, bacterial

Genetic Tests for Bacterial Vaginosis

Anatomical Context for Bacterial Vaginosis

MalaCards organs/tissues related to Bacterial Vaginosis:

38
Testes, Colon, Breast, Bone, T Cells, Cervix, Neutrophil

Publications for Bacterial Vaginosis

Articles related to Bacterial Vaginosis:

(show top 50) (show all 721)
# Title Authors Year
1
The effect of<i>Calendula officinalis</i>versus metronidazole on bacterial vaginosis in women: A double-blind randomized controlled trial. ( 29441319 )
2018
2
Combined oral and topical antimicrobial therapy for male partners of women with bacterial vaginosis: Acceptability, tolerability and impact on the genital microbiota of couples - A pilot study. ( 29293559 )
2018
3
Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. ( 29196153 )
2018
4
Bacterial vaginosis modifies the association between hormonal contraception and HIV acquisition. ( 29334545 )
2018
5
Reply to letter to editor regarding: Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception compared to levonorgestrel-releasing intrauterine system. ( 29323559 )
2018
6
Is bacterial vaginosis a disease? ( 29177936 )
2018
7
Are previous episodes of bacterial vaginosis a predictor for vaginal symptoms in breast cancer patients treated with aromatase inhibitors? ( 29409388 )
2018
8
Corynebacterium fournierii sp. nov., isolated from the female genital tract of a patient with bacterial vaginosis. ( 29383461 )
2018
9
Microbial Culturomics Broadens Human Vaginal Flora Diversity: Genome Sequence and Description of Prevotella lascolaii sp. nov. Isolated from a Patient with Bacterial Vaginosis. ( 29447068 )
2018
10
A Phase 3, Multicenter, Prospective, Open-Label Study to Evaluate the Safety of a Single Dose of Secnidazole 2a88g for the Treatment of Women and Postmenarchal Adolescent Girls with Bacterial Vaginosis. ( 29323627 )
2018
11
Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment. ( 29327947 )
2018
12
<i>'Lactobacillus raoultii'</i> sp. nov., a new bacterium isolated from the vaginal flora of a woman with bacterial vaginosis. ( 29204281 )
2018
13
Bacterial vaginosis, human papilloma virus and herpes viridae do not predict vaginal HIV RNA shedding in women living with HIV in Denmark. ( 28569142 )
2017
14
Treatment failure of bacterial vaginosis is not associated with higher loads of Atopobium vaginae and Gardnerella vaginalis. ( 28792372 )
2017
15
Bacterial vaginosis: A practical review. ( 29135564 )
2017
16
Association of asymptomatic bacterial vaginosis with persistence of female genital human papillomavirus infection. ( 28681204 )
2017
17
Prevalence and distribution of Gardnerella vaginalis subgroups in women with and without bacterial vaginosis. ( 28583109 )
2017
18
Comparisons of vaginal flora patterns among sexual behaviour groups of women: implications for the pathogenesis of bacterial vaginosis. ( 29212588 )
2017
19
Cervical carcinogenesis, bacterial vaginosis, HPV-mRNA test and relapse of CIN2+ after loop electrosurgical excision procedure (LEEP). ( 28617533 )
2017
20
Multiplex PCR detection of problematic pathogens of clinically heterogeneous bacterial vaginosis in Bulgarian women ( 29151321 )
2017
21
Prevalence of bacterial vaginosis in Portuguese pregnant women and vaginal colonization by Gardnerella vaginalis. ( 28875084 )
2017
22
Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. ( 28697102 )
2017
23
Screening for bacterial vaginosis before intrauterine device insertion at a family planning clinic in south-west Nigeria. ( 28762360 )
2017
24
Prevalence of Bacterial Vaginosis and Associated Risk Factors among Women Complaining of Genital Tract Infection. ( 28831285 )
2017
25
Thermoplastic polyurethane-based intravaginal rings for prophylaxis and treatment of (recurrent) bacterial vaginosis. ( 28663088 )
2017
26
Treatment for Symptomatic Bacterial Vaginosis: ARandomized Controlled Trial. ( 29132478 )
2017
27
Correction: Jang, S.-E.; et al. Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus La-14 Attenuate Gardnerella vaginalis-Infected Bacterial Vaginosis in Mice. Nutrients 2017, 9, 531. ( 28686189 )
2017
28
Risk of bacterial vaginosis, Trichomonas vaginalis and Candida albicans infection among new users of combined hormonal contraception vs LNG-IUS. ( 28849960 )
2017
29
Self-taken vaginal swabs versus clinician-taken for detection of candida and bacterial vaginosis: a case-control study in primary care. ( 29158246 )
2017
30
Multiplex Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA-FISH) for Diagnosis of Bacterial Vaginosis. ( 28600771 )
2017
31
Gemini Cationic Amphiphiles Control Biofilm Formation by Bacterial Vaginosis Pathogens. ( 28893789 )
2017
32
No. 211-Screening and Management of Bacterial Vaginosis in Pregnancy. ( 28729110 )
2017
33
Bacterial vaginosis and the risk of early miscarriage in women undergoing intracytoplasmic sperm injection cycles: a prospective cohort study. ( 28738736 )
2017
34
Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV. ( 29198180 )
2017
35
The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. ( 28807017 )
2017
36
Redox imbalance correlates with high Nugent score in bacterial vaginosis. ( 29239072 )
2017
37
Bacterial Vaginosis and Cervical Intraepithelial Neoplasia: Is there an Association or is Co-Existence Incidental? ( 28610416 )
2017
38
Treatment of biofilms in bacterial vaginosis by an amphoteric tenside pessary-clinical study and microbiota analysis. ( 28903767 )
2017
39
A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. ( 28867602 )
2017
40
Brief report: Associations between antecedent bacterial vaginosis and incident chlamydia and gonorrhea diagnoses, U.S. Army females, 2006-2012. ( 26930150 )
2016
41
Association of Bacterial Vaginosis With Chlamydia and Gonorrhea Among Women in the U.S. Army. ( 27816380 )
2016
42
Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses. ( 27449868 )
2016
43
Association between bacterial vaginosis and partner concurrency: a longitudinal study. ( 27645157 )
2016
44
Women's Management of Recurrent Bacterial Vaginosis and Experiences of Clinical Care: A Qualitative Study. ( 27010725 )
2016
45
Can one size fit all? Approach to bacterial vaginosis in sub-Saharan Africa. ( 26968525 )
2016
46
Bacterial vaginosis, aerobic vaginitis, vaginal inflammation and major Pap smear abnormalities. ( 26810061 )
2016
47
Cannonballs in Pap Smears: Double Whammy of Bacterial Vaginosis and Associated Infections. ( 26981615 )
2016
48
The treatment of bacterial vaginosis in pregnancy with clindamycin to reduce the risk of infection-related preterm birth: a response to the Danish Society of Obstetrics and Gynecology guideline group's clinical recommendations. ( 27874978 )
2016
49
Women's Views and Experiences of the Triggers for Onset of Bacterial Vaginosis and Exacerbating Factors Associated with Recurrence. ( 26930414 )
2016
50
Antimicrobial susceptibility and vaginolysin in Gardnerella vaginalis from healthy and bacterial vaginosis diagnosed women. ( 27694723 )
2016

Variations for Bacterial Vaginosis

Expression for Bacterial Vaginosis

Search GEO for disease gene expression data for Bacterial Vaginosis.

Pathways for Bacterial Vaginosis

Pathways related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 CXCL8 DEFB4A IL10 IL1A IL1B IL6
2
Show member pathways
13.61 CXCL8 IL10 IL1A IL1B IL6 TLR4
3
Show member pathways
13.42 CXCL8 IL10 IL1A IL1B IL6 TLR2
4
Show member pathways
13.32 CXCL8 IL10 IL1A IL1B IL6 TNF
5
Show member pathways
13.26 CXCL8 IL10 IL1A IL1B IL6 TNF
6
Show member pathways
13.02 CXCL8 IL1A IL1B IL6 TLR2 TLR4
7
Show member pathways
12.92 CXCL8 IL10 IL1A IL1B IL6 PRF1
8
Show member pathways
12.87 CXCL8 IL1A IL1B IL6 TLR2 TLR4
9
Show member pathways
12.75 IL1A IL1B IL6 TLR2 TLR4 TNF
10
Show member pathways
12.68 CXCL8 IL1B IL6 TNF
11
Show member pathways
12.65 IL10 IL1A IL1B IL6 TLR2 TLR4
12
Show member pathways
12.64 IL1A IL1B TLR2 TLR4 TNF
13
Show member pathways
12.61 CXCL8 IL6 TLR2 TLR4 TNF
14
Show member pathways
12.58 CXCL8 IL10 IL1B IL6 TLR2 TLR4
15
Show member pathways
12.57 IL10 IL1B IL6 TNF
16 12.54 IL10 IL1B TLR2 TNF
17
Show member pathways
12.49 IL10 IL1A IL1B IL6 TNF
18
Show member pathways
12.43 CXCL8 DEFB4A IL1B IL6 TLR2 TNF
19
Show member pathways
12.37 CXCL8 IL1A IL6 TLR2 TLR4 TNF
20
Show member pathways
12.36 CXCL8 IL1A IL1B IL6 TLR4 TNF
21
Show member pathways
12.35 IL10 IL1A IL1B TLR2 TLR4 TNF
22
Show member pathways
12.25 IL1A IL1B TLR4 TNF
23 12.25 CXCL8 IL10 IL1A IL1B IL6 TNF
24 12.25 IL10 IL1A IL1B IL6 TLR2 TLR4
25 12.22 IL6 TLR2 TLR4 TNF
26
Show member pathways
12.22 CXCL8 IL10 IL1A IL1B IL6 TNF
27
Show member pathways
12.19 CXCL8 DEFB4A IL1B IL6 TLR2 TLR4
28 12.13 CXCL8 IL1A IL6
29
Show member pathways
12.09 IL1A IL1B TLR2 TLR4
30 12.08 CXCL8 IL1A IL1B IL6 TLR4 TNF
31 12.06 IL1A IL1B TNF
32 12.04 CXCL8 IL10 IL1A IL1B IL6 TNF
33 12.02 IL1A IL1B TNF
34 12.02 CXCL8 IL1A IL1B IL6
35 12.02 CXCL8 IL1A IL1B IL6 TNF
36
Show member pathways
11.99 IL10 IL1B IL6 TLR2 TLR4 TNF
37 11.98 IL10 IL6 TNF
38 11.98 IL1A IL1B IL6 TNF
39 11.96 CXCL8 IL1B TLR4 TNF
40 11.95 CXCL8 IL1A IL1B IL6 TLR4
41 11.94 IL1B IL6 TNF
42
Show member pathways
11.93 IL1B IL6 TLR2 TLR4
43
Show member pathways
11.87 CXCL8 IL6 TLR4
44 11.85 CXCL8 IL10 IL1B IL6 TLR2 TLR4
45 11.84 IL10 IL1B IL6 TNF
46 11.81 IL10 IL6 TLR2 TLR4 TNF
47 11.8 IL10 IL1B TNF
48
Show member pathways
11.77 CXCL8 IL1A IL1B IL6 TNF
49 11.76 CXCL8 IL1B IL6 TNF
50 11.65 CXCL8 IL1A IL1B IL6 TLR2 TLR4

GO Terms for Bacterial Vaginosis

Cellular components related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 CXCL8 DEFB4A IL10 IL1A IL1B IL6
2 extracellular region GO:0005576 9.23 CXCL8 DEFB4A IL10 IL1A IL1B IL6

Biological processes related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 CXCL8 IL10 IL1A IL1B IL6 TLR2
2 positive regulation of gene expression GO:0010628 9.95 IL1A IL1B IL6 TLR2 TLR4 TNF
3 defense response to bacterium GO:0042742 9.94 DEFB4A IL10 TLR4 TNF
4 response to lipopolysaccharide GO:0032496 9.93 IL10 IL1B TLR2 TLR4
5 cytokine-mediated signaling pathway GO:0019221 9.9 IL1A IL1B IL6
6 defense response GO:0006952 9.89 CXCL8 DEFB4A TNF
7 positive regulation of angiogenesis GO:0045766 9.89 CXCL8 IL1A IL1B
8 activation of MAPK activity GO:0000187 9.88 IL1B TLR4 TNF
9 positive regulation of DNA binding transcription factor activity GO:0051091 9.86 IL10 IL1B IL6 TNF
10 defense response to Gram-negative bacterium GO:0050829 9.85 DEFB4A IL6 TLR4
11 defense response to Gram-positive bacterium GO:0050830 9.85 DEFB4A IL6 TLR2 TNF
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 IL1B IL6 TLR2 TLR4 TNF
13 positive regulation of JNK cascade GO:0046330 9.84 IL1B TLR4 TNF
14 response to glucocorticoid GO:0051384 9.83 IL10 IL6 TNF
15 cellular response to lipopolysaccharide GO:0071222 9.83 CXCL8 IL10 IL6 TLR4 TNF
16 positive regulation of interferon-gamma production GO:0032729 9.79 IL1B TLR4 TNF
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 IL1B TLR4 TNF
18 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.77 IL1A IL1B TNF
19 positive regulation of cytokine secretion GO:0050715 9.76 IL10 IL1A TNF
20 inflammatory response GO:0006954 9.76 CXCL8 IL10 IL1A IL1B IL6 TLR2
21 negative regulation of interleukin-6 production GO:0032715 9.75 IL10 TLR4 TNF
22 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.72 IL10 TNF
23 embryonic digestive tract development GO:0048566 9.71 CXCL8 TNF
24 negative regulation of lipid catabolic process GO:0050995 9.71 IL1B TNF
25 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 IL1B TNF
26 positive regulation of macrophage activation GO:0043032 9.71 IL10 TLR4
27 negative regulation of growth of symbiont in host GO:0044130 9.71 IL10 TNF
28 lipopolysaccharide-mediated signaling pathway GO:0031663 9.71 IL1B TLR2 TLR4 TNF
29 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.7 IL1B TNF
30 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.7 TLR2 TLR4
31 I-kappaB phosphorylation GO:0007252 9.7 TLR2 TLR4
32 response to molecule of bacterial origin GO:0002237 9.7 CXCL8 IL10 TLR2
33 regulation of cytokine secretion GO:0050707 9.69 TLR2 TLR4
34 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.69 IL1A IL1B
35 positive regulation of monocyte chemotactic protein-1 production GO:0071639 9.69 IL1A IL1B
36 cellular response to lipoteichoic acid GO:0071223 9.68 TLR2 TLR4
37 negative regulation of lipid storage GO:0010888 9.68 IL6 TNF
38 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IL1B TNF
39 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.67 TLR4 TNF
40 endothelial cell apoptotic process GO:0072577 9.67 IL10 TNF
41 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL10 IL1B TNF
42 positive regulation of interleukin-8 production GO:0032757 9.67 IL1B TLR2 TLR4 TNF
43 regulation of establishment of endothelial barrier GO:1903140 9.66 IL1B TNF
44 ectopic germ cell programmed cell death GO:0035234 9.66 IL1A IL1B
45 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL10 TLR4
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.65 IL10 TNF
47 fever generation GO:0001660 9.64 IL1A IL1B
48 positive regulation of fever generation GO:0031622 9.63 IL1B TNF
49 sequestering of triglyceride GO:0030730 9.62 IL1B TNF
50 positive regulation of NF-kappaB import into nucleus GO:0042346 9.62 IL1B TLR2 TLR4 TNF

Molecular functions related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.16 IL1A IL1B
2 cytokine activity GO:0005125 9.1 CXCL8 IL10 IL1A IL1B IL6 TNF
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4

Sources for Bacterial Vaginosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....